Skip to content
Review Open access

Emerging and Re-Emerging Viral Pathogens in Oncolytic Virotherapy: A Comprehensive Review.

Aug 2026 · Reviews in Medical Virology · Vol 36 5, pp. e70167 · 0 citations · 62 references
Medicine

TL;DR

The present review provides a comprehensive overview of novel viral candidates in oncolytic virotherapy, their molecular mechanisms of tumour targeting, and current advancements in genetic engineering aimed at improving therapeutic efficacy and biosafety.

Abstract

Oncolytic virotherapy has recently emerged as a promising immuno-oncological strategy, utilising the natural cytolytic potentials of viral pathogens to selectively target and destroy malignant cells. Although various engineered viruses, such as adenoviruses, vaccinia virus, and herpes simplex virus, are currently in clinical evaluation, emerging and re-emerging viruses with intrinsic oncolytic potential, including Zika virus (ZIKV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Dengue virus (DENV), and West Nile virus (WNV), have also shown promising results. These emerging and re-emerging viral pathogens show specific tumour tropism, immune evasion strategies, and immunogenic cell death mechanisms that could be harnessed for next-generation therapeutic platforms. Nonetheless, concerns related to safety, viral pathogenicity, host immune responses, and the risk of uncontrolled viral dissemination present significant translational challenges. The present review provides a comprehensive overview of novel viral candidates, including ZIKV, SARS-CoV-2, DENV, and WNV, in oncolytic virotherapy, their molecular mechanisms of tumour targeting, and current advancements in genetic engineering aimed at improving therapeutic efficacy and biosafety. Moreover, this review describes clinical perspectives, regulatory considerations, and future directions in integrating emerging virotherapeutic agents into precision oncology.

Read PDF

Similar papers

Review Open access Oct 2026

Oncolytic virotherapy for cancer: biological mechanisms, clinical advances, and future perspectives

Oncolytic virotherapy has emerged as a promising cancer treatment that combines selective tumor destruction with potent stimulation of antitumor immunity. Unlike conventional therapies, oncolytic viruses (OVs) preferentially infect and replicate within malignant cells while sparing normal tissues, leading to direct tum...

Esraa M. Halawa, Sherihan G. Abdelhamid, Mahmoud M. Elhefnawi · 0 citations
Review Sep 2026

Next-generation Oncolytic Virotherapy: Genetic Engineering, Immune Modulation, Advanced Delivery Platforms and Clinical Progress

Oncolytic Virotherapy (OVT) is an emerging area of cancer immunotherapy that has shown promise as a therapeutic agent, leveraging genetically engineered replication- competent viruses that kill cancer cells without harming normal cells. HSV-1 (T-VEC), vaccinia, and adenoviruses. Immuno-Oncology Oncol Ther 2017; Mon...

Indu Arora, Shalu Attar, Priyanka Bhardwaj et al. · 0 citations
Review Open access Sep 2026

Nanotechnology-Enabled Therapeutics for Global Viral Diseases: From COVID-19 to Emerging Viral Infections

This review aims at assessing the latest advancements in the field of nanotechnology in terms of developing therapeutic interventions in viral diseases, especially COVID-19 and other emerging viral infections.

Abhishek Kumar, Anamika Gaurishankar Parihar · 0 citations
Review Open access Sep 2026

Harnessing Coordinated CD4⁺ and CD8⁺ T-Cell Immunity for Virus-Specific Adoptive Immunotherapy in Africa

Virus-specific T-cell (VST) therapy has developed principally for persistent or reactivating viral infections in immunocompromised patients, with the strongest clinical experience involving cytomegalovirus, Epstein–Barr virus, human adenovirus, BK polyomavirus and human herpesvirus 6. Whether this approach can be exten...

Caroline Mangare · 0 citations
Review Open access Oct 2026

Targeting Toll-like Receptors to Enhance Oncolytic Virotherapy: Strategies and Emerging Perspectives

Oncolytic virotherapy (OVT) is a promising anticancer strategy, owing to its capacity to lyse tumor cells selectively and remodel the tumor microenvironment (TME) to enhance antitumor efficacy. Despite the continuous introduction and investigation of newly engineered oncolytic viruses (OVs) in clinical trials, their cl...

Si-Qian Lan, Xiao-Qiang Hao, Dong-Ming Zhou et al. · 0 citations
Review Oct 2026

Overcoming glioma heterogeneity: Strategies to improve the specificity of oncolytic viruses.

This review examines how genetic, transcriptional, metabolic, epigenetic, and immune heterogeneity influence viral entry, replication, dissemination, and therapeutic activity in glioma and compares established and emerging platforms.

A. Romanishin, K. Rubina, E. Semina · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.